161 related articles for article (PubMed ID: 16197310)
1. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance.
Teerlink T
Clin Chem Lab Med; 2005; 43(10):1130-8. PubMed ID: 16197310
[TBL] [Abstract][Full Text] [Related]
2. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
[TBL] [Abstract][Full Text] [Related]
4. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
5. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
Blackwell S
Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
7. Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia.
Mao D; Che J; Li K; Han S; Yue Q; Zhu L; Zhang W; Li L
Arch Gynecol Obstet; 2010 Oct; 282(4):371-5. PubMed ID: 19806356
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow.
Selcuk MT; Selcuk H; Temizhan A; Maden O; Ulupinar H; Baysal E; Ozeke O; Sasmaz A
Coron Artery Dis; 2007 Nov; 18(7):545-51. PubMed ID: 17925608
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
Böger RH
Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
11. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?
Bouras G; Deftereos S; Tousoulis D; Giannopoulos G; Chatzis G; Tsounis D; Cleman MW; Stefanadis C
Curr Top Med Chem; 2013; 13(2):180-200. PubMed ID: 23470077
[TBL] [Abstract][Full Text] [Related]
13. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Wilcken DE; Sim AS; Wang J; Wang XL
Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
[TBL] [Abstract][Full Text] [Related]
15. Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU).
Huemer M; Simma B; Mayr D; Möslinger D; Mühl A; Schmid I; Ulmer H; Bodamer OA
J Inherit Metab Dis; 2012 Sep; 35(5):817-21. PubMed ID: 22290024
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of homocysteine and asymmetric dimethylarginine in human urine by liquid chromatography-tandem mass spectrometry.
Gopu CL; Hari PR; George R; Harikrishnan S; Sreenivasan K
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():32-7. PubMed ID: 24095873
[TBL] [Abstract][Full Text] [Related]
17. [Asymmetric dimethylarginine as cardiovascular risk factor].
Galán A; Formiguera X; Rey-Joly C
Med Clin (Barc); 2008 Sep; 131(7):271-5. PubMed ID: 18775219
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort.
Schwedhelm E; Xanthakis V; Maas R; Sullivan LM; Schulze F; Riederer U; Benndorf RA; Böger RH; Vasan RS
Clin Chem; 2009 Aug; 55(8):1539-45. PubMed ID: 19541865
[TBL] [Abstract][Full Text] [Related]
19. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism.
Ozcan O; Cakir E; Yaman H; Akgul EO; Erturk K; Beyhan Z; Bilgi C; Erbil MK
Clin Endocrinol (Oxf); 2005 Aug; 63(2):203-6. PubMed ID: 16060915
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
van Guldener C; Nanayakkara PW; Stehouwer CD
Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
